Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Bioavailability Study of DW340 vs DW330SR + DW1030
NCT02380976Phase 1Completed
- Sponsor
- Daewon Pharm
- Start
- Oct 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of pelubiprofen and eperisone in acute low back pain (2 arms), sponsored by Daewon Pharm. Primary endpoints: Maximum Plasma Concentration (Cmax) of DW330SR at 9 days, Maximum Plasma Concentration (Cmax) of DW340 at 9 days and 4 more. Started Oct 2015; status: completed.
02
Drugs
pelubiprofeneperisone
03
Conditions
acute low back pain
Beyond the preview
Go deeper on NCT02380976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02380976.